Cited by 160Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Open access

Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weber, Manuel, Herrmann, Ken, Spanke, Maximilian, Fendler, Wolfgang P., Hadaschik, Boris, Kleesiek, Jens, Schäfers, Michael, Weckesser, Matthias, Boegemann, Martin, Rahbar, Kambiz·2021·European Journal of Nuclear Medicine and Molecular Imaging

DOI 10.1007/s00259-020-05040-1PMC PMC8041668

Open this paper in CoChat — free account Open PDF

Abstract

Abstract Introduction [ 177 Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. Methods A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUV mean ), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUV mean) were quantified for each patient. Log2 transformation was used for regressions. Results Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. Conclusion PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00259-020-05040-1

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Quartiles of PSMA tumor volume and overall survival. (a) depicts boxplots of the PSMA tumor volume (PSMA-TV) quartile 1 to quartile 4. The overall survival is separately shown for each PSMA-TV quartile (b). Exemplary patients of each quartile were shown together with blood levels of prostate-specific antigen (PSA) (c–f)CC BY · PubMed Central

Fig. 2 Quartiles of PET and blood biomarkers and overall survival. Patients were stratified on the basis of PSMA-TLU quartiles (a), PSMA-TLQ quartiles (b), prostate-specific antigen blood level quartiles (c), and lactate dehydrogenase blood level quartiles (d)CC BY · PubMed Central

Fig. 3 PSMA-TV and PSMA-TLQ and overall survival. Quintile 1, quintiles 2–4, and quintile 5 of PSMA-TV (a) or PSMA-TLQ (b) were employed to stratify patients and compare the median estimated overall survival between the strata. Number at risk tables were given by (c) and (d), respectively. Boxplots of quintile 1, quintiles 2–4, and quintile 4 were separately shown for PSMA-TV (e) and PSMA-TLQ (f)CC BY · PubMed Central

Fig. 4 Stratification of PSMA-TV or PSMA-TLQ by ideal log rank cutoffs. A log rank cutoff finder was employed for PSMA-TV (a) or PSMA-TLQ (b) to form groups and compare the estimated median overall survival. Additionally, a number at risk tables were shown for PSMA-TV (c) and PSMA-TLQ (d). Boxplots of PSMA-TV (e) and PSMA-TLQ (f) were shown as wellCC BY · PubMed Central

Fig. 5 Baseline parameters and survival of Münster and Essen cohort. Patients form the university hospital Münster (UHM) or Essen (UHE) were compared with regard to overall survival (a), cumulated Lu-PSMA dose (b), prostate-specific antigen blood levels (c), and lactate dehydrogenase blood levels (d). No statistically significant differences were observedCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Kyriakopoulos, C. E., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,108
German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citation
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
On the exact distribution of maximally selected rank statistics
Hothorn, T., & Lausen, B. (2003) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(02)00225-6 · Cited by 694
Metastatic prostate cancer
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Dosimetry of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504 · cited 2×
“In line with the concept of theranostics, high SUVmean is associated with higher tumor doses of Lu-PSMA therapy and should therefore be linked to a favorable outcome [25].”
Background
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461

Show all 26 references

Sorted by citations

Items 101–160 of 160

Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17203330 · Cited by 5
The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects
Civan, C., Karpinski, M. J., Rahbar, K., Fendler, W. P., & Herrmann, K. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.12.003 · Cited by 3
Self-citation
PSMA PET/CT–Derived Indicators and Outcomes After [ 177 Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program
Kimura, K., Murthy, V., Voter, A. F., Sólnes, L. B., Tuchayi, A. M., Yadav, S., Theus, L., Nguyen, A. T., Ludwig, V. B., Holzgreve, A., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270789 · Cited by 3
Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?
Kaplan, İ., Kömek, H., Can, C., Akdeniz, N., Güzel, Y., Kepenek, F., Şenol, A., Ileri, S., Karaoğlan, H., Solmaz, I., et al. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-024-01954-0 · Cited by 3
Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen
Tayara, O., Poletajew, S., Malewski, W., Kunikowska, J., Pełka, K., Kryst, P., & Nyk, Ł. (2024) · Current Oncology · doi:10.3390/curroncol31080311 · Cited by 3
Treatment‐related changes in the prostate: past, present and future therapies
Collins, K., & Liang Cheng, C. (2025) · Histopathology · doi:10.1111/his.15507 · Cited by 3
Prognostic value of pretherapeutic 68 Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligands
Nikoukar, L. R., Seifert, R., Ventura, D., Schindler, P., Bögemann, M., Rahbar, K., & Roll, W. (2024) · NuclearMedicine · doi:10.1055/a-2383-2468 · Cited by 2
Self-citation
SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
Bodar, Y. J. L., Koene, B. P. F., Jansen, B. H. E., Cysouw, M. C. F., Meijer, D., Hendrikse, N. H., Vis, A. N., Boellaard, R., & Oprea‐Lager, D. E. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.260232 · Cited by 3
A comparison between two image reconstructions on the measures of prostate-specific membrane antigen–positive tumor volume in 18F-PSMA-JK-7-PET/computed tomography
Ufton, D., Heilinger, J., Roth, K. S., Schmidt, M., Drzezga, A. E., & Kobe, C. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002021 · Cited by 2
Prognostic Value of Early Follow-Up PSMA PET/CT After 2 Cycles of [ 177 Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics
Widjaja, L., Hornfeck, J., Siegmund, S. C., Gildehaus, F. J., Delker, A., Schmidt-Hegemann, N.-S., Rowe, S. P., Casuscelli, J., Stief, C., Zacherl, M. J., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271859 · Cited by 2
Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review
Collins, K., & Liang Cheng, C. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.02.007 · Cited by 2
Improving sensitivity through data augmentation with synthetic lymph node metastases for AI‐based analysis of PSMA PET‐CT images
Trägårdh, E., Ulén, J., Enqvist, O., Edenbrandt, L., & Larsson, M. (2024) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12879 · Cited by 2
Association of [68Ga]Ga-PSMA-11 PET/CT Metrics with PSA Persistence Following Radical Prostatectomy in Patients with Intermediate- and High-Risk Prostate Cancer
Rosales, J. J., Betech-Antar, V., Mínguez, F., Guillén, E. F., Prieto, E., Quincoces, G., Beorlegui, C., de la Maza, M. D. F., Diez-Caballero, F., López, B. M., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15030301 · Cited by 2
Prostate-specific Membrane Antigen
Seifert, R., Gafita, A., Sólnes, L. B., & Iagaru, A. H. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.002 · Cited by 2
Self-citation
Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
Cheng, J., Adhami, M., Pham, T., Nadebaum, D. P., Baring, A., Paul, E. M., Cherk, M. H., & Grummet, J. (2025) · BJUI Compass · doi:10.1002/bco2.70015 · Cited by 1
The effect of androgen blockade on [68Ga]Ga-PSMA-11 and [18F]FDG PET uptake in patients with recurrent or metastatic salivary duct carcinoma: a prospective imaging study
van Ruitenbeek, N. J., Uijen, M. J. M., Driessen, C. M. L., van Rijk, M. C., Peters, S. M. B., Privé, B. M., Verhaegh, G. W. C. T., Grunsven, A. C. H. V. E., Gotthardt, M., Nagarajah, J., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01275-x · Cited by 1
A Narrative Review of Recent Advances in Prostate-Specific Membrane Antigen (PSMA)-Based Diagnostics and Theranostics
Pasha, A. A., Hajiebrahimi, N., Motallebi, N., & Eydi, M. (2025) · Studies in Multidisciplinary Medical Research · doi:10.61882/smmr.202501.07.02 · Cited by 1
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [ 225 Ac]Ac-PSMA Radiopharmaceutical Therapy
Widjaja, L., Siegmund, S. C., Gildehaus, F. J., Delker, A., Schmidt-Hegemann, N.-S., Pomper, M. G., Rowe, S. P., Bundschuh, R. A., Wenter, V., Sheikh, G. T., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270677 · Cited by 1
Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making
Bardoscia, L., Camilli, F., Triggiani, L., Ciurlia, E., Iori, F., Festa, E., Trovò, M., Lancia, A., Detti, B., & Ingrosso, G. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2677891 · Cited by 1
Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics
Fanti, S., Turco, F., TOMBAL, B. F., Walz, J. C., Hofman, M. S., Hadaschik, B. A., Emmett, L., Tilki, D., Pecoraro, G., Salfi, G., et al. (2026) · European Urology · doi:10.1016/j.eururo.2026.06.009 · Cited by 1
Self-citation
Prostate-Specific Membrane Antigen-Ligand Therapy
Rowe, S. P., Sadaghiani, M. S., Gafita, A., Sheikhbahaei, S., Pomper, M. G., Young, J., Spitz, A. N., Werner, R. A., Oldan, J. D., & Sólnes, L. B. (2023) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2023.07.003 · Cited by 1
115 T市幼児ことばの教室における1歳6ヶ月児健診の経過観察における小集団指導のこころみ(2)
京林, 由., 細川, か., & 菅野, 敦. (1990) · 日本保育学会大会研究論文集
PET imaging of prostate cancer
Ong, J. S. L., & Hofman, M. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00111-3
Digitale Positronenemissionstomografie – Entwicklung, Detektortechnologie und Perspektiven
Kazek, S. L., Jentzen, W., Seifert, R., Herrmann, K., & Kersting, D. (2022) · Angewandte Nuklearmedizin · doi:10.1055/a-1715-5184
Self-citation
Desenvolvimento e aplicação de método semiquantitativo do esqueleto total em exames de 18F-NaF PET/CT: estabelecimento de valores normais em pacientes não metastáticos e avaliação prognóstica em pacientes com metástases ósseas
Marin, J. F. G. (2023) · doi:10.11606/t.5.2023.tde-19062023-124316
Early Detection of Prostate Cancer using PSMA PET
Bodar, Y. J. L. (2023) · doi:10.5463/thesis.231
Pharmacometric approaches to improve theranostics
Siebinga, H. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1920
Predictive value of metastatic distribution patterns on [68Ga]Ga-PSMA PET/CT for [177Lu]Lu-PSMA therapy
Cayirli, Y. B., Elboğa, U., & Dogan, I. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2025.500205
Valor predictivo de los patrones de distribución metastásica en la PET/TC con [68Ga]Ga-PSMA PET/CT en el tratamiento con [177Lu]Lu-PSMA
Cayirli, Y. B., Elboğa, U., & Dogan, I. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2025.500205
Performance of PSMA PET-CT imaging in predicting outcomes and assessing response in prostate cancer: a meta-analysis
Zhou, S., Ren, H., Zhu, K., & Cheng, S. (2025) · International Journal of Radiation Research · doi:10.61882/ijrr.23.3.22
Predicting hematologic toxicity of lutetium-177 prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer using pretreatment gallium-68 prostate-specific membrane antigen positron emission tomography imaging: preliminary data in Asian patients
Huang, Y.-Y., Huang, K., & Lee, P. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002086
Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial
Chen, W., Yoshida, S., Kimura, K., Arita, Y., & Fujii, Y. (2025) · European Urology Focus · doi:10.1016/j.euf.2025.11.019
Additional file 1 of Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
Siebinga, H., Hendrikx, J. J. M. A., Huitema, A. D. R., & de Wit-van der Veen, B. J. (2024) · Figshare · doi:10.6084/m9.figshare.26597333
Additional file 1 of Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value
Bela Andela, S., Amthauer, H., Furth, C., Rogasch, J. M. M., Beck, M., Mehrhof, F. B., Ghadjar, P., van den Hoff, J., Klatte, T., Tahbaz, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26755660
Additional file 1 of Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer
Peterson, J. R., Cole, J. A., Pfeiffer, J. R., Norris, G. H., Zhang, Y., Lopez-Ramos, D., Pandey, T., Biancalana, M., Esslinger, H. R., Antony, A. K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26588484
Integral Approach in the Follow-up of Prostate Cancer Patients: SOGUG Multidisciplinary Expert Panel Insights
Méndez-Vidal, M. J., Gallardo, E., Iturriaga, A. G., López‐Campos, F., Ballesteros, C. M., Vozmediano, J. R., del Alba, A. G., & Rodríguez, J. M. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102489
PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT)
Späth, M. S., Dittmann, H., Spallek, R., Calderón, E., Mück, J., Brendlin, A., Rausch, S., la Fougère, C. J., & Trautwein, N. F. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07712-2
Prognostic value of tumour volume based on [18F]PSMA-1007 PET/CT in prostate cancer
Ingvar, J., Wittgren, J., Sverrisdóttir, V., Trägårdh, E., & Bjartell, A. (2026) · EJNMMI Reports · doi:10.1186/s41824-026-00292-w · Cited by 1
Head-to-head comparison between 18F-FDG and 18F-PSMA-1007 PET/CT in diagnosing recurrent and metastatic prostate cancer
Wang, N., You, J., Kong, W., Zhu, Y., Hong, Z., Yang, Y., Shi, Y., & Pei, Z. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08045-w
Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer
Murugesan, G., Moore, S., Chang, A. C., Mancini, B. R., & Kulkarni, H. R. (2026) · PET Clinics · doi:10.1016/j.cpet.2026.02.005
Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Atasever, T., Babacan, G. B., Ekinci, Ö. B., Büyükkuşcu, A., Soylu, B., Kabaca, F. Z. Y., Atçı, M. M., Karyağar, S., Ertürk, K., & Çelik, E. (2026) · Cancer Imaging · doi:10.1186/s40644-026-01036-6
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer
Cren, P., Buteau, J. P., Fatema, U., Patel, R., Saraiya, B., Emmett, L., & Fizazi, K. S. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516658
PSMA-directed nanoprobe enabling precision imaging and MR-guided chemoradiotherapy in prostate cancer
Feng, B., Zhang, X., Cai, J., Zhang, Q., Liu, Z., Shi, Y., Akhmetova, D. R., Shipilovskikh, S. A., Bao, Y., 熊梦华, et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114994
Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy
Mercier, B., Dréano, L., Neveu, E., Estrade, F., Mathiéu, R., Laguerre, B., Crouzet, L., Broyelle, A., Bouvry, C., Jeune, F. L., et al. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02236-7
Development and evaluation of improved in-house procedure for radiolabelling of theranostic agent [177Lu]Lu-PSMA-617
Jukic, N., Huić, D., Žuvić, M., Nemet, I., & Rončević, S. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00462-y
FDG PET/CT Beyond Mismatch Exclusion in [177Lu]Lu-PSMA Therapy: Baseline Prognosis and Response Assessment
Kassas, M., Léger, M.-A., Poenaru, R., Tahmi, D., Zeiter, R. L., Shagera, Q., Abadi, Y., Karfis, I., Flamen, P., & Artigas, C. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100234
The Prognostic Value of 68Ga-PSMA and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-EB-PSMA
Chen, X., Peng, Y., Zheng, Q., Lai, Y., Cheng, H., Zhu, Z., Wang, G., & Zang, J. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02250-9
Development and Advantages of O -(Carboxymethyl)- L -tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer
Li, L., Zhao, R., Wang, G., Jin, W., Zhu, L., Zhu, Z., & Kung, H. F. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00960
Baseline PSMA PET/CT Biomarkers for Patient Selection in [177Lu]Lu-PSMA Radioligand Therapy: Clinical Promise, Methodological Heterogeneity and Future Standardization
Galnaitienė, G., Simkus, M., Balčiūnaitė, I., Lušaitė, K., Wen, F., Hoffmann, M., Saar, M., Mottaghy, F. M., Vajauskas, D., & Lütje, S. (2026) · Pharmaceuticals · doi:10.3390/ph19071084
Evaluating Interim Progression: First Posttherapy 177 Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT
Parihar, A. S., Dehdashti, F., Pant, N., Ravindra, S. G., Pachynski, R. K., Picus, J., Reimers, M. A., Bhatt, A., Gay, H., Song, W., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272545
Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis
Molin, K., Li, S., Barry, N., Ong, J. S. L., Iravani, A., Hofman, M. S., Hassan, G. M., Ebert, M. A., & Kendrick, J. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102628
PSMASegmentator: Open-source, AI-based software for PSMA PET/CT automatic segmentation and prognostic biomarker extractionPreprint
Noble, J. I. M., Hiwase, M. D., Barry, N., Rowshanfarzad, P., Ebert, M. A., Ong, J. S. L., O'Callaghan, M., Sweeney, C. J., To, M., Dell’Oro, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10609412/v1
FDG/PSMA discordance in [177Lu]Lu-PSMA radioligand therapy for mCRPC: a provisional target-sufficiency framework
Deng, J., Ma, G., Chen, W., Wen, S., & Chen, N. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1935673
Augmenting Deep Learning-Based PSMA PET/CT Metastasis Segmentation With a Population-Level Spatial AtlasPreprint
Chau, G. N., Biswas, B. A., Wagle, B. R., Maeder, M. E., Yu, J. B., & Bhattacharya, I. (2026) · medRxiv · doi:10.64898/2026.08.26.26361439
Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [ 177 Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy
Zhao, R., Li, M., Lv, J., Zhang, J., Zhong, H., Fu, Y., Liu, J., Gu, D., Zeng, G., Kung, H. F., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272406
The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer
Akgüner, G., İlhan, A., & Yıldırım, Ö. A. (2026) · Biomedicines · doi:10.3390/biomedicines14102160
The Role of Artificial Intelligence in PET Imaging.
Veziroglu, E. M., Dayma, K., Hasani, N., Kulkarni, R., Farhadi, F., & Klyuzhin, I. (2026) · The Radiologic clinics of North America · doi:10.1016/j.rcl.2026.07.010
Reconstruction robustness of liver-referenced adaptive thresholding for 68Ga-PSMA-11 PET/CT volumetry: a comparative analysis of systematic bias and individual-patient variability
Schötz, E., Ufton, D., Weindler, J. J., Schmidt, M. C., Roth, K. S., Drzezga, A. E., & Kobe, C. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02298-7
Prognostic Value of Baseline High-Uptake PSMA Tumor Volume Fraction in Metastatic Castration-Resistant Prostate Cancer Patients Treated with [177Lu]Lu-PSMA Radioligand Therapy
Cuzzocrea, M., Pecoraro, G., Iacovitti, C. M., Martinello, C., Treglia, G., Gillessen, S., Pedrani, M., & Paone, G. (2026) · Cancers · doi:10.3390/cancers18203297
Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
Ebrahimifard, A., Bagheri, S., Wang, Q., Shamami, A. H., Fazio, P. D., Eilsberger, F., Müller, L., Luster, M., Librizzi, D., & Yousefi, B. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209330

Authors: Seifert, R., Kessel, K., Schlack, K., Weber, M., Herrmann, K., Spanke, M., Fendler, W. P., Hadaschik, B., Kleesiek, J., Schäfers, M., Weckesser, M., Boegemann, M., & Rahbar, K.
Affiliations: University Hospital Münster (DE)
Essen University Hospital (DE)
German Cancer Research Center (DE)
Corresponding author: Rahbar, Kambiz
ORCID: Seifert, Robert
Kessel, Katharina
Schlack, Katrin
Weber, Manuel
Herrmann, Ken
Fendler, Wolfgang P.
Hadaschik, Boris
Kleesiek, Jens
Schäfers, Michael
Weckesser, Matthias
Rahbar, Kambiz
Venue: European Journal of Nuclear Medicine and Molecular Imaging
Publisher: Springer Science and Business Media LLC
Published: 2020-09-24
Volume: 48
Issue: 4
Pages: 1200-1210
ISSN: 1619-7070 (ISSN-L)
1619-7089
DOI: 10.1007/s00259-020-05040-1
PMC: PMC8041668
OpenAlex: W3088497176
Cited by: 160
References: 26
Citations by year: 2026: 31 · 2025: 31 · 2024: 25 · 2023: 26 · 2022: 20 · 2021: 24 · 2020: 2
FWCI: 8.77
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Funders: Westfälische Wilhelms-Universität Münster
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords: 177Lu-PSMA-617, radioligand therapy, advanced prostate cancer, PSMA PET/CT, total tumor volume, prognostic factors, overall survival, PSMA-617, PSMA-11, tumor volume measurement
MeSH terms: Positron Emission Tomography Computed Tomography, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Retrospective Studies, Treatment Outcome, Prostate-Specific Antigen, Tumor Burden, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks